

U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated November 18, 2013,
1. Acquisition Bell Hospital, LLC d/b/a Bell Hospital	3. License No. 21-02037-03 is renewed in its entirety to read as follows:
2. 901 Lakeshore Drive Ishpeming, Michigan 49849	4. Expiration Date: February 29, 2024
	5. Docket No. 030-13856 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged kits	D. 5 millicuries

9. Authorized Use:

- A. Any uptake, dilution or excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. In vitro studies.

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 901 Lakeshore Drive, Ishpeming, Michigan.
- 11. The Radiation Safety Officer (RSO) for this license is Todd K. Bostwick, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
21-02037-03

Docket or Reference No.
030-13856

Amendment No. 21

12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the materials and uses indicated:
- | <u>Authorized User</u> | <u>Material and Use</u> |
|----------------------------|-----------------------------------|
| Todd K. Bostwick, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| Raymond A. Wood, Jr., D.O. | 10 CFR 35.200. |
13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 18, 2013; and,
- B. Letter dated December 16, 2013.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION



Date FEB 19 2014

By

Bryan A. Parker
Materials Licensing Branch
Region III